DAUNOXOME
LOE Approachingdaunorubicin citrate
NDAINJECTIONINJECTABLE, LIPOSOMALPriority Review
Approved
Apr 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 5d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DAUNOXOME is a liposomal formulation of daunorubicin citrate, an anthracycline chemotherapy agent approved in 1996. It is indicated for treatment of advanced HIV-associated Kaposi's sarcoma and functions as a cytotoxic agent that intercalates DNA and inhibits topoisomerase II. The liposomal encapsulation improves drug delivery and reduces cardiotoxicity compared to conventional daunorubicin.
LOE Approaching
Product is in late-stage lifecycle with 30% competitive pressure; expect portfolio transition planning and potential team consolidation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on DAUNOXOME offers limited career growth due to its LOE-approaching status and minimal linked job openings. This product is best suited for professionals in medical affairs or field roles focused on market maintenance and stakeholder relationship preservation.
Medical Science LiaisonOncology Field Sales
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.